LianBio Enters into Agreement with Bristol Myers Squibb for

LianBio to receive total upfront consideration of $350 millionLianBio Board of Directors to conduct strategic review of business SHANGHAI and PRINCETON, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the company has entered into an agreement with Bristol Myers Squibb (BMS), whereby BMS has obtained LianBio’s exclusive rights to develop and c

Related Keywords

China , Australia , Brazil , South Korea , Taiwan , Thailand , Macau , Canada , United Kingdom , Shanghai , Switzerland , Hong Kong , Singapore , Great Britain , Yizhe Wang , Josh Xu , Elizabeth Anderson , Adam Lenkowsky , Bristol Myers Squibb , China National Medical Products Administration , Vp Communications , Centerview Partners , Myokardia Inc , European Union , York Heart Association , Exchange Commission , Bio Board , Mainland China , Priority Review , New Drug Application , Chief Executive Officer , Chief Commercialization Officer , Bristol Myers , Lianbio Board , New York Heart Association , Annual Report , Investor Relations , Asian Markets , Lianbio , Clinical Development , Hypertrophic Cardiomyopathy , Biotechnology Company ,